Association between triglyceride glucose index and depression in polycystic ovary syndrome
- PMID: 40259312
- PMCID: PMC12010597
- DOI: 10.1186/s12902-025-01927-y
Association between triglyceride glucose index and depression in polycystic ovary syndrome
Abstract
Objective: The relationship between the triglyceride glucose (TyG) index and the incidence of depression in populations with polycystic ovary syndrome (PCOS) remains unclear. This study aims to investigate the relationship between the TyG index and depression incidence in PCOS populations.
Methods: We conducted a study on 725 women aged 18 to 45 who visited our hospital from January 2021 to December 2023. Demographic and anthropometric data were collected, and serum assays were performed. The Center for Epidemiologic Studies Depression Scale (CES-D) was used to assess the past week's feelings and determine depression status. Statistical methods such as binary logistic regression analysis were used to analyze the relationship between the TyG index, Homeostatic model assessment insulin resistance index(HOMA-IR), and depression in PCOS patients. The TyG index, HOMA-IR, was tested for its ability to predict depression using receiver operating characteristic (ROC) curves.
Results: In logistic regression models, a significant positive association was observed between the TyG index and depression after the adjusted analysis(4.552(2.975 ∼ 6.966), P<0.001). Compared to HOMA-IR(1.224(1.122 ∼ 1.336), P<0.001), the TyG index was a more significant risk factor for depression. ROC analysis showed that the AUC of the TyG index(0.724, 0.684 ∼ 0.765) was higher than the HOMA-IR(0.698,0.656~0.74).
Conclusions: A high TyG index was associated with higher odds of having depression in the population with PCOS. This indicated that the TyG index may be an independent predictor of depression development.
Clinical trial number: Not applicable.
Keywords: Depression; Insulin resistance(IR); Polycystic ovary syndrome (PCOS); Triglyceride glucose (TyG) index.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The study was approved by the Ethics Committee of Yuyao People’s Hospital (protocol code: 2022-03-014), and informed consent was obtained from participants. The Protocol of the current study was performed in accordance with the Declaration of Helsinki standards. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Supplementary information: The online version contains supplementary material available at https://www.scidb.cn/anonymous/TmZNM1ly .
Figures


Similar articles
-
Association of insulin resistance surrogates with live birth outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization.BMC Pregnancy Childbirth. 2025 Jan 11;25(1):25. doi: 10.1186/s12884-024-07131-5. BMC Pregnancy Childbirth. 2025. PMID: 39799297 Free PMC article.
-
Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women.Lipids Health Dis. 2020 Nov 8;19(1):235. doi: 10.1186/s12944-020-01410-8. Lipids Health Dis. 2020. PMID: 33161896 Free PMC article.
-
Value of the triglyceride-glucose index and non-traditional blood lipid parameters in predicting metabolic syndrome in women with polycystic ovary syndrome.Hormones (Athens). 2023 Jun;22(2):263-271. doi: 10.1007/s42000-023-00438-6. Epub 2023 Feb 15. Hormones (Athens). 2023. PMID: 36790635
-
Evaluation of Triglyceride Glucose Index and Homeostasis Model of Insulin Resistance in Patients with Polycystic Ovary Syndrome.Int J Womens Health. 2022 Dec 23;14:1821-1829. doi: 10.2147/IJWH.S387942. eCollection 2022. Int J Womens Health. 2022. PMID: 36582617 Free PMC article.
-
Significance of measuring anthropometric and atherogenic indices in patients with polycystic ovary syndrome.BMC Endocr Disord. 2024 Aug 28;24(1):160. doi: 10.1186/s12902-024-01701-6. BMC Endocr Disord. 2024. PMID: 39198818 Free PMC article.
References
-
- Revised. 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004;19(1):41– 7. - PubMed
-
- Alvarez YR, Pico M, Ashokprabhu N, Abou-Amro K, Bailey S, Pung E, et al. Polycystic ovarian syndrome: a risk factor for cardiovascular disease. Curr Atheroscler Rep. 2023;25(12):1003–11. - PubMed
-
- Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020;30(7):399–404. - PubMed
-
- Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international Evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120(4):767–93. - PubMed
-
- Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075–91. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous